Extinct Species as Fundraising Tool
Colossal Biosciences
Colossal is using spectacle as a financing tool for hard biotech infrastructure. Mammoths, dodos, and dire wolves turn abstract platform work, like genome editing, reproductive biology, and species specific cell culture, into stories that investors, governments, and recruits can quickly understand. That matters because the company needs large upfront funding to build labs, hire elite scientists, and run many expensive experiments before any conservation or commercial products produce revenue.
-
The funding pattern shows the attention loop in action. Colossal had raised $555 million by September 17, 2025, and tied that financing to visible de extinction programs including dodo, mammoth, and dire wolf work. Those flagship species give investors concrete milestones to follow, even though the underlying assets are enabling tools and know how.
-
The same platform is already being extended into living species work. Colossal says its conservation network includes more than 50 partners, and recent programs span endangered species biobanking, pink pigeon and northern quoll genetic rescue, northern white rhino work, and wildlife disease projects. That makes the extinct animal narrative a top of funnel for broader conservation technology deployment.
-
This is closer to a biotech platform company than a one product moonshot. The company describes revenue paths in IP, software, cell banking, and spinouts, which means a mammoth or dodo program can justify investment in tools that later sell into governments, zoos, breeding programs, and conservation groups across many species.
The next phase is a shift from headline species to repeatable infrastructure. If Colossal keeps converting animal specific breakthroughs into shared tools, like avian germ cell culture, biobanking, cloning, and genetic rescue workflows, the business can evolve from a story driven de extinction company into a broader conservation and biodiversity technology platform.